BridgeBio Pharma Inc.

BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines for genetic diseases and cancers with clear genetic drivers. Its primary focus is on tackling significant unmet medical needs in the rare disease sector, particularly those affecting pediatric and neurodevelopmental health. BridgeBio Pharma is notable for its pipeline that includes gene therapies, such as the investigational BBP-812 for Canavan disease, which aims to become the first therapeutic option for this severe neurodevelopmental disorder if approved. The company employs advanced technologies, including adeno-associated virus (AAV)-based gene therapies, and collaborates with leading academic and medical institutions. BridgeBio Pharma's mission is to translate genetic insights into targeted therapies, positioning it as a key player in the biopharmaceutical industry’s drive to address rare and underserved conditions.